Recent News

• 03.19.2026 - OKYO Pharma Announces Director Acquires Shares
• 03.19.2026 - OKYO Pharma Announces Chief Development Officer and Director Acquires Shares
• 03.18.2026 - OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain
• 02.13.2026 - OKYO Pharma Announces Pricing of $20 Million Public Offering of Ordinary Shares
• 02.12.2026 - OKYO Pharma Announces Public Offering of Ordinary Shares
• 02.11.2026 - OKYO Pharma Announces Transition of At-The-Market Equity Offering Facility to Leerink Partners

Recent Filings

• 03.12.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.23.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.23.2026 - EX-99.1 EX-99.1
• 02.18.2026 - SCHEDULE 13G Statement of Beneficial Ownership by Certain Investors
• 02.17.2026 - 424B5 Prospectus [Rule 424(b)(5)]
• 02.13.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.13.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]
• 02.13.2026 - SCHEDULE 13G/A Statement of Beneficial Ownership by Certain Investors
• 02.13.2026 - EX-99.1 EX-99.1
• 02.12.2026 - 6-K Report of foreign issuer [Rules 13a-16 and 15d-16]